Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and development expenses. Research and development expenses in the second quarter of 2009 were $10.5 million, compared to $6.2 million in the second quarter of 2008. The increase was primarily due to manufacturing scale-up expenses and expenses to prepare regulatory filings related to the Company's fidaxomicin and prulifloxacin programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of June 30, 2009, Optimer held cash, cash equivalents and short-term investments of $51.2 million.

"During the second quarter, we had the first oral presentations of our North American Phase 3 fidaxomicin data at major scientific conferences showing that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence of CDI, even in high risk patient populations," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "As we head into the second half of this year, we look forward to presenting additional data from this study at ICAAC and IDSA and we are focused on completing our second fidaxomicin Phase 3 trial and preparing regulatory filings for fidaxomicin and prulifloxacin."

Recent Corporate Highlights

  • Clinical inves
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...blue dye test alternative is helping bring comple...tep closer for pharma-companies. It is a non-destr...ed by Sepha for use with blister packs and it ha...al pharma-companies such as Sanofi-Avenis and Zydu...ivity improvements on the packaging line. Bliste...
(Date:11/25/2009)...Speak at Economic Club of Canada , ...9 -- Ambassador to Speak at Economic Club of Canad...or International Investment, and Chairman and CEO ...y of David Appia go to www.investinfrance.org . ...with press to discuss recent pro-business initiati...
(Date:11/25/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Brazil Bioethanol Market Analysis and F...om/p0165503/Brazil-Bioethanol-Market-Analysis-and-...rket Analysis and Forecasts to 2013 ,, Summary...forecasts of the global bioethanol market and the ...
(Date:11/24/2009)...also Visit Detroit , (Voc...ench Ambassador for International Investment, and ... , , ,What: Ambassador Appia is available to meet...ives adopted by France to further develop the fina...n and development., , ,When: Available for Intervi...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10
...lvania and OXFORD, England, May 9 ,EUSA Pharma Inc...l company,focused on oncology, pain control and cr... its acquisition of Cytogen Corporation, following...al meeting on 8 May., Under the terms of the acqu...ve $0.62 per share, valuing the company at $22.6 m...
...CAMBRIDGE, Mass., May 9 ,Takeda Pharmaceutical Com...,Pharmaceuticals, Inc., "Millennium" (Nasdaq: MLN...akeda,s cash tender offer by its wholly-owned,subs... outstanding shares,of Millennium common stock for... for the tender offer expired at 12:00,midnight, N...
...Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) annou...t at,the Bank of America 2008 Healthcare Conferenc...p.m. Eastern Time) at the Four Seasons Hotel in La...Senior Vice President and,Chief Scientific Officer...ny, including its clinical development and discove...
Other Biology Technology:EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 5Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3
(Date:11/24/2009)... matter of debate. A high-profile study a few year... their carbon from trees and leaves, evidence for ...tic ecosystems. , But new research from the Univ...e true. Algae provide a much richer diet for fish ...ished this week in the Proceedings of the Nationa...
(Date:11/23/2009)...associated strain of the deadly superbug MRSAan in...antibioticsposes a far greater health threat than ...als, according to a study in the December issue of...at is easily picked up in fitness centers, schools...erall burden of MRSA within hospitals, the report ...
(Date:11/23/2009)...participants gathered this week for the seventh an...nference. This year,s topic, "Synthetic Biology," ...l researchers to explore the engineering, scientif...ld of synthetic biology. , Bonnie L. Bassler, pr...ty and this year,s conference chair, challenged th...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes 6203 1Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes 6203 2Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes 6203 3Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes 6203 4Orexigen 28R 29 Therapeutics to Speak at Lazard Capital Markets Healthcare Conference 6198 1Behavior modification could ease concerns about nanoparticles 10701 1Behavior modification could ease concerns about nanoparticles 10701 2
...g, Va. -- A veterinary neurologist on faculty in t...y Medicine( www.vetmed.vt.edu ) at Virginia Tech h...rsity Translational Science Institute to study inn...gs, cats and humans. , Dr. John Rossmeisl, an ass... Clinical Sciences (DSACS), is working with Wake F...
...gian Tooth Bank is requesting milk teeth from 100 ...t tooth bank in the world. Milk teeth can give un...d nutrition in the foetus and in early childhood. ...Mother and Child Cohort Study (MoBa), and is a col... of Public Health and the University of Bergen. ,...
...e earliest general anaesthetics to be used by the ...a mystery thats puzzled doctors for more than 150 ...iscovery described as true serendipity made by Lee...ovided a clue that may unravel the enigma of gener...n new generations of anaesthetics without harmful ...
Other Biology News:Veterinary college researcher studying brain tumors in people and animals 2Veterinary college researcher studying brain tumors in people and animals 3Tooth Bank seeks milk teeth from 100,000 children 2Chloroform provides clue to 150 year old medical puzzle 2
...xcellent choice for supporting hydrocarbon process...nel GC, this one-channel workhorse can double samp...one. You get all the capability and reliability yo...at has the same proven performance of Agilents fla...
...nfusion kits reduce the time and expense of prepar...equipment to reduce the risk of infection. Each ki...luding swivel, tubing, tether and connectors. Tubi...u specify, preassembled in Instech's clean room, i...
7890A GC from Agilent Technologies
... for critical, but time-consuming optimization exp...siRNA transfection protocols resulting in less opt...an be used to efficiently transfect adherent cells...xicity. From start to finish, successful gene sile...
Biology Products: